A combined analysis of data over years in patients in Phase 2 trials of supports benefits for those up to age 65 and moderate ...

For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields ...

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that anti-PD-L1 immunotherapy in ...

Results from a phase 3 clinical trial show promise for a new standard of care for treating people with advanced cervical ...

Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance ...

Jazz Pharmaceuticals contends that its alkylating agent Zepzelca significantly improved both overall survival and progression ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

In some with grade 3 brain cancer, adding PCV chemotherapy regimen to radiation showed better survival outcomes than another ...

Therapeutics announces new survival data, outperforming patients, and survival rates in its Phase 2 metastatic breast cancer ...

Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...

BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current ...

A study published in Clinical Cancer Research confirmed that tissue stiffening in the most common types of breast cancer, HER2-negative, can directly cause disease progression and metastasis, leading ...